Bluejay Diagnostics, Inc. (BJDX) Stock

Bluejay Diagnostics, Inc. (BJDX) is a Healthcare stock trading at $0.92 (as of 2026-08-20), with a market capitalization of $4.11M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Bluejay Diagnostics, Inc. develops and sells the Symphony platform, including the Symphony analyzer for whole-blood processing, biomarker isolation, and immunoassay preparation, along with Symphony Cartridges containing reagents and components. It also provides the ALLEREYE point-of-care diagnostic test for allergic conjunctivitis and develops Symphony IL-6 tests for critical care monitoring.

Understand Bluejay Diagnostics, Inc.: how it makes money

Bluejay Diagnostics develops and sells medical diagnostics, including the Symphony platform (a Symphony analyzer plus Symphony Cartridges containing reagents and components) and the ALLEREYE point-of-care test device for allergic conjunctivitis, with additional development of Symphony IL-6 tests for critical care monitoring.

The business combines a diagnostic analyzer platform with consumable-style Symphony Cartridges (reagents and components) used to run tests, creating a repeat usage linkage between the installed analyzer and cartridge-based revenue.

Business quality (Weak): The product set is coherent around a platform plus cartridges and point-of-care testing, but the provided latest quarter figures show revenue of 0.0B and a very large negative operating margin, leaving profitability and demand visibility as key concerns.

Bull case

  • Platform plus cartridge workflow: The Symphony technology includes the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation, paired with the Symphony Cartridge that includes reagents and components.
  • Multiple diagnostic offerings: Bluejay also offers ALLEREYE, a point-of-care device for diagnosis of allergic conjunctivitis, and is developing Symphony IL-6 tests for monitoring disease progression in critical care settings.

Bear case

  • Profitability is currently very weak in the provided results: For the period ended 2026-03-31, the operating margin is reported as -10280.7%, indicating large operating losses.
  • Limited revenue visibility in the provided data: The latest reported period shows revenue of 0.0B, which makes it harder to assess traction based on the figures provided.
Valuation — source: SEC EDGAR (first-party)
Price$0.92
Market Cap$4.11M
Price / Book0.44
Price / Sales50.48
FCF Yield-157.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$97559.00
Net Margin-7019.8%
Revenue Growth (YoY)-33.1%
EPS Growth (YoY)-86.6%
FCF Growth (YoY)-23.4%
Financial Health — source: SEC EDGAR
Altman Z-Score-10.17 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderSABBY MANAGEMENT, LLC ($52856.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOIndranil Dey
Employees7
CountryUS
IPO Date2021-11-10

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Intelligent Bio Solutions Inc. (INBS)
  • Co-Diagnostics, Inc. (CODX)
  • enVVeno Medical Corporation (NVNO)
  • Picard Medical, Inc. (PMI)
  • Autonomix Medical, Inc. Common Stock (AMIX)
  • Catheter Precision, Inc. (VTAK)
  • Sonoma Pharmaceuticals, Inc. (SNOA)
  • Amundi Core MSCI Emerging Markets UCITS ETF EUR Dist (AEMD)
BJDX earnings history · BJDX institutional & insider holders · BJDX KPIs & operating metrics · BJDX financials · BJDX investor presentations & press releases · BJDX SEC filings · BJDX peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.